UPDATE: Piper Jaffray Upgrades Cepheid Following In-Line 2Q13 Results
In a report published Friday, Piper Jaffray analyst William R. Quirk upgraded Cepheid (NASDAQ: CPHD) from Neutral to Overweight, and raised the price target from $37.00 to $43.00.
In the report, Piper Jaffray noted, “Cepheid reported 2Q13 results in-line with the preliminary announcement. Encouragingly, management resolved its recent manufacturing-related allocation issues and investments to improve manufacturing are a priority. Management increased F2013 revenue guidance to $380M-$385M (was $375M-$385M), but lowered its EPS outlook to reflect the inventory charge and additional manufacturing operations investments (now ($0.30)-($0.27), was ($0.05)-$0.01). We are upgrading CPHD shares to Overweight from Neutral with a $43 price target (was $37) based on ~7x (was 6x) CY14E CDx revenue + ~1.5x CY14E base revenue. We suspect competitive noise heading into/during the upcoming AACC meeting could create some share price volatility, but view CMS' upcoming Hospital IQR decision (potentially adding MRSA & C. diff as new chart abstracted HAI measures for FY16) and viral load (FY14 U.S., FY15 U.S.) as significant potential catalysts, justifying our higher multiple and price target.”
Cepheid closed on Thursday at $34.14.
Latest Ratings for CPHD
|Apr 2015||JMP Securities||Maintains||Market Outperform|
|Dec 2014||Bank of America||Upgrades||Neutral||Buy|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.